Patent Continuations: One Specification, Years of New Claims

A patent is often treated as a finish line: the application is filed, the patent issues, the work is done. For anyone building something competitors will eventually build too, that framing leaves real value on the table. The continuation is the mechanism that keeps a patent family working for years after the first filing, and it is one of the most underused tools in US patent practice.

Last updated: July 2026. Educational only, not legal advice, and not a prediction for any specific application. Primarily US law and USPTO practice; other jurisdictions differ. Consult a registered patent practitioner about your situation.

What a continuation actually is

A continuation application is a new application that pursues a new set of claims from the same disclosure as an earlier ("parent") application. Same specification, same drawings, same priority date. What changes is only what you are asking the Office to grant: different claim language, covering different scope, drawn from what the original application already described.

Two things make this powerful:

• The priority date is preserved. Claims in a continuation are treated as of the parent's filing date for subject matter the parent disclosed (35 U.S.C. §120, subject to the written-description requirement of §112(a)). You are not restarting the clock; you are drawing new claims against an early priority position.
• No new matter is allowed. A continuation lives entirely inside the original disclosure. The moment you add technical content the parent did not describe, it is no longer a continuation.

The family: continuation, divisional, continuation-in-part

These three are frequently confused, and the differences are legally significant.

The CIP carries a trap worth stating plainly: newly added matter gets only the later filing date. New matter is not free. There is also a wrinkle from the America Invents Act (AIA). A CIP filed on or after March 16, 2013 becomes subject to the AIA first-inventor-to-file regime if it contains, or ever contained, a claim whose effective filing date (the date a claim is actually entitled to, which is the parent's only where the parent supports it) falls on or after that date, which is what happens when a claim depends on the new matter for support. A CIP whose claims are all fully supported by a pre-AIA parent does not automatically lose pre-AIA treatment, and mixed families get a more complicated answer still (pre-AIA §102(g) can continue to apply alongside AIA §§102 and 103). Check the chain claim by claim rather than by filing date alone. See MPEP 2159.

The rules that make it work

• Copendency. A continuation must be filed while the parent is still pending, that is, on or before the date the parent patent issues (the Federal Circuit addressed same-day filing in Immersion). Once the parent issues, abandons, or proceedings terminate, that door is closed. Practitioners commonly file the continuation before paying the issue fee on the parent, which is why a well-run portfolio treats "file the continuation" as a checkpoint at allowance rather than an afterthought.
• A common inventor. At least one inventor must be shared between the continuation and the parent, across the whole priority chain.
• An explicit reference chain. The continuation must specifically reference the parent and name the relationship, so copendency is established through the entire chain of prior applications (MPEP 211).
• Inventorship follows the new claims. At least one inventor must be shared for §120 benefit, but inventorship in the continuation is determined by what its claims actually cover. Because continuation claims often target a different embodiment or contribution, the named inventors may need to change, which in turn touches assignment paperwork, former employees and contractors, and chain of title. Code authorship is evidence of contribution, not the legal test: someone can conceive without implementing, and someone who only implements another's complete conception may not be an inventor. See AI and patent inventorship.
• Term runs from the earliest benefit claim. The 20-year term is generally measured from the earliest US non-provisional or qualifying international application in the benefit chain (§§120, 121, 365(c), 386(c)), not from the continuation's own filing date. A US provisional and a foreign priority claim generally do not start that clock. A continuation does not restart the term or extend the family's ordinary statutory term; it extends your ability to keep drafting new claims within it. Patent term adjustment (PTA) can add days to an individual patent, so "same clock" is the rule rather than an absolute.

A request for continued examination (RCE) is not a continuation. The two get confused constantly. An RCE reopens prosecution in the same application; it is not a new application and cannot be used as of right to switch to an independent and distinct invention. A continuation is a new application with its own number and its own claims, resting on the prior disclosure and benefit chain. If you need different claims to a different invention, an RCE is not the vehicle.

The companion issue: double patenting and terminal disclaimers

Any discussion of continuations that stops at priority and term is incomplete. Because a continuation claims a variation of the same disclosure, obviousness-type double patenting (ODP) is the routine objection, and the routine answer is a terminal disclaimer that ties the continuation's expiration to the parent's.

That has a real cost. In In re Cellect (Fed. Cir. 2023), the court held that ODP for a patent that received patent term adjustment must be assessed against the expiration date after PTA is added, so earlier-expiring members of a family can be used to attack later-expiring ones. The practical consequence: PTA earned on one family member can be given back through a terminal disclaimer. Statutory double patenting separately reaches claims that are identical, and nonstatutory ODP reaches claims that are not patentably distinct, which is why continuation claims should pursue genuinely different scope rather than restate the parent's.

A terminal disclaimer is not a free fix. Beyond cutting term, it typically conditions enforceability on the patents remaining commonly owned, which matters later during spinouts, acquisitions, portfolio sales, and any attempt to license or assign family members separately. A continuation is not just another claim set; it is a new asset with consequences for how the whole family can be transferred.

One related trap for the divisional column above: the §121 safe harbor against double patenting is not automatic just because an application is labeled a divisional. It generally depends on the divisional being filed in response to a restriction requirement (the examiner requiring that an application covering more than one independent invention be split), filed while the parent is pending, and maintaining consonance with the restricted groups, meaning the claims stay lined up with the inventions as the examiner divided them. General framework: MPEP 804.

The sharpest reason: disclosed but unclaimed can be dedicated to the public

There is a doctrine that turns continuations from a nice-to-have into something closer to a duty. Under the disclosure-dedication rule of Johnson & Johnston Associates v. R.E. Service Co., 285 F.3d 1046 (Fed. Cir. 2002) (en banc), subject matter that a patent discloses but does not claim is dedicated to the public. Johnston's specification described aluminum and also mentioned steel substrates, but the claims covered only aluminum. When a competitor used steel, Johnston could not reach it through the doctrine of equivalents, the rule that can catch something outside the literal words of a claim but insubstantially different from it. The disclosed alternative was gone.

That is the doctrine that gives continuation practice its edge. If your specification carefully described three architectures and your issued claims literally cover one, equivalents may not rescue the other two. A continuation is the mechanism for seeking literal claims to what you already disclosed, subject to support and patentability.

It also sharpens the question a practitioner should actually ask at allowance: which commercially relevant alternatives did this specification expressly teach that the family has never literally claimed?

Which leads to the line worth remembering: a continuation is not a second chance to add what you forgot. It is a second chance to claim what you actually disclosed.

Why they matter: the strategic case

A continuation is optionality. You paid to write a rich specification once; a continuation lets you keep drawing on that disclosure as the world changes.

• Aim at competitors who arrive later. The market rarely looks the same three years after filing. If a competitor's product reads on something your specification described but did not claim, a continuation lets you draft claims that read on that product even though it did not exist when you filed. This is expressly permitted: in Kingsdown Medical v. Hollister (Fed. Cir. 1988) the court held there is nothing improper in amending or inserting claims intended to cover a competitor's product learned about during prosecution, provided the statutory requirements are met. The outer limit is prosecution laches, which the Federal Circuit has applied to unreasonable delay in the Hyatt litigation; that doctrine is under active Supreme Court attention, so confirm current treatment.
• Adjust scope as the invention proves out. Continuation claims can be broader or narrower than the parent's. Early claims are often conservative; a continuation lets you go broader once you understand what actually matters, or narrower and more defensible once you see the prior-art landscape. Our Claim Scope Ladder is the worksheet for that decision: each rung is a candidate claim concept, checked for §112 support and validity exposure.
• Keep competitors uncertain. A pending continuation means protectable scope is not yet fixed, and competitors cannot design around claims that are still being written.
• Portfolio value. A single well-drafted specification can become a multi-patent family with years of claim flexibility, which is part of why acquirers and licensees look at whether continuations are still pending.

The mental model that captures it: the specification is the asset, and each continuation is a fresh option written against that asset while the clock runs. That is also why the quality of the original disclosure matters so much. See how to write a strong disclosure and the Invention Disclosure Form.

Where AI helps, and where it does not

Continuation drafting is unusually well suited to AI assistance, for a specific reason: the hard input, a rich specification, already exists. The task is to find claim scope the specification supports but the parent never claimed, and to draft that scope in proper form. That is a language task grounded in a fixed document, which is where current models are strongest.

An AI drafting aid can surface disclosed but unclaimed subject matter across a long specification faster than a manual re-read, draft candidate claim sets in proper US form with correct antecedent basis, and check drafting quality: written-description support against the spec (§112(a)), definiteness (§112(b)), claim form, and differentiation from the parent's claims.

The limits have to be stated as plainly as the capabilities:

• Fluency is not support. A model will happily draft a claim on an embodiment the specification never disclosed, in flawless claim language. The grounding check exists precisely because the raw draft cannot be trusted on it.
• AI does not determine patentability. Novelty and non-obviousness require a prior-art search and legal judgment a drafting tool does not perform. A tool that scores drafting quality is not telling you whether a claim will be granted. See the §103 worksheet and the §101 worksheet for the analyses that do sit with counsel.
• The practitioner is accountable for every filing. Under the USPTO's Guidance on Use of AI-Based Tools in Practice Before the USPTO (applicable April 11, 2024), the existing duties apply unchanged when AI is used: the duty of candor and good faith, and the certifications every signer makes under 37 CFR 11.18 for each paper filed. A registered practitioner signs, and owns, every claim submitted under their name.

That is the posture worth insisting on: AI drafts and measures drafting quality; a licensed practitioner exercises independent professional judgment over every output and makes the legal calls. Used that way it compresses the mechanical part of continuation drafting, exploring and forming claim options, so the practitioner spends time on the parts that need a lawyer: which scope to pursue, against which competitor, and whether it will hold. Related: AI and patent inventorship.

When a continuation is not worth filing

Availability is not a reason. Not every allowance should trigger another application, and a page that only argues the upside is not much use at the moment of the decision. The considerations that actually decide it:

• How clearly the disclosure supports the scope you would pursue, which is a §112 question before it is a strategy question.
• Whether the unclaimed scope is commercially relevant, or merely available.
• How much term is left, since the clock runs from the earliest benefit claim rather than the new filing.
• Prior-art and eligibility exposure on the scope you would seek.
• Whether infringement of the resulting claims would be observable and provable from outside a product, which is where server-side steps and multi-actor methods get hard.
• Inventorship and ownership consequences of claims aimed at a different contribution.
• Double-patenting and terminal-disclaimer effects on term and on transferability.
• Prosecution and maintenance cost against expected value.
• Whether the newer implementation you have in mind is actually inside the original disclosure at all, or is new matter that a continuation cannot reach.

There is also a public-interest side worth stating plainly, because it is what keeps the tool legitimate: no new matter may be added, earlier benefit depends on actual disclosure support, the ordinary family term is not restarted, double-patenting doctrine guards against unjustified extension, and unreasonable delay can raise prosecution-laches concerns. The flexibility is real, and it is bounded.

The takeaway

A continuation turns one specification into a durable, adaptable asset. It lets a patent family aim at threats that did not exist at filing, adjust scope as the invention and the market mature, and stay valuable to acquirers, all within the original 20-year term and subject to the double-patenting tradeoffs above. It is a practitioner's tool, and the drafting work inside it, finding supported scope and forming it into clean claims, is exactly the part AI can accelerate, provided the tool is honest about the line between drafting quality and legal determination, and a licensed professional stays in the loop.

Filing your first application rather than extending a family? Start with provisional patent strategy.

Sources